These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Mode of interaction of beta-hydroxy-beta-methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds. Nakamura CE; Abeles RH Biochemistry; 1985 Mar; 24(6):1364-76. PubMed ID: 3886005 [TBL] [Abstract][Full Text] [Related]
25. Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. Sliskovic DR; Roth BD; Wilson MW; Hoefle ML; Newton RS J Med Chem; 1990 Jan; 33(1):31-8. PubMed ID: 2296027 [TBL] [Abstract][Full Text] [Related]
26. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744 [TBL] [Abstract][Full Text] [Related]
27. Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. Karanewsky DS; Badia MC; Ciosek CP; Robl JA; Sofia MJ; Simpkins LM; DeLange B; Harrity TW; Biller SA; Gordon EM J Med Chem; 1990 Nov; 33(11):2952-6. PubMed ID: 2231594 [No Abstract] [Full Text] [Related]
28. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Yamamoto A; Itoh S; Hoshi K; Ichihara K Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284 [TBL] [Abstract][Full Text] [Related]
30. Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. Roth BD; Ortwine DF; Hoefle ML; Stratton CD; Sliskovic DR; Wilson MW; Newton RS J Med Chem; 1990 Jan; 33(1):21-31. PubMed ID: 2296019 [TBL] [Abstract][Full Text] [Related]
31. Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Procopiou PA; Draper CD; Hutson JL; Inglis GG; Ross BC; Watson NS J Med Chem; 1993 Nov; 36(23):3658-62. PubMed ID: 8246234 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of hepatic cholesterol biosynthesis by a 3-hydroxy-3-methylglutaryl coenzyme A synthase inhibitor, 1233A, in mice. Nagashima H; Kumagai H; Tomoda H; Omura S Life Sci; 1993; 52(19):1595-600. PubMed ID: 8097863 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. Beck G; Kesseler K; Baader E; Bartmann W; Bergmann A; Granzer E; Jendralla H; von Kerekjarto B; Krause R; Paulus E J Med Chem; 1990 Jan; 33(1):52-60. PubMed ID: 2296036 [TBL] [Abstract][Full Text] [Related]
34. Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. Chan C; Bailey EJ; Hartley CD; Hayman DF; Hutson JL; Inglis GG; Jones PS; Keeling SE; Kirk BE; Lamont RB J Med Chem; 1993 Nov; 36(23):3646-57. PubMed ID: 8246233 [TBL] [Abstract][Full Text] [Related]
35. Feedback-type inhibition of activity of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ubiquinone. Omkumar RV; Gaikwad AS; Ramasarma T Biochem Biophys Res Commun; 1992 May; 184(3):1280-7. PubMed ID: 1590790 [TBL] [Abstract][Full Text] [Related]
36. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
37. Hypocholesterolemic agents III: inhibition of beta-hydroxy-beta-methylglutaryl coenzyme A reductase by half acid esters of 1-(4-biphenylyl)pentanol. Guyer KE; Boots SG; Marecki PE; Boots MR J Pharm Sci; 1976 Apr; 65(4):548-52. PubMed ID: 1271253 [TBL] [Abstract][Full Text] [Related]
38. Design of a highly potent inhibitory peptide acting as a competitive inhibitor of HMG-CoA reductase. Pak VV; Koo M; Kwon DY; Yun L Amino Acids; 2012 Nov; 43(5):2015-25. PubMed ID: 22451276 [TBL] [Abstract][Full Text] [Related]
39. 3-Hydroxy-3-methylglutaryl coenzyme A reductase in anencephalic and normal human fetal liver. Carr BR; Rainey WE; Mason JI J Clin Invest; 1985 Nov; 76(5):1946-9. PubMed ID: 2997298 [TBL] [Abstract][Full Text] [Related]
40. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Keller RK; Zhao Z; Chambers C; Ness GC Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]